首页 > 最新文献

Indian Journal of Allergy Asthma and Immunology最新文献

英文 中文
Role of immunological mediators in the follow-up of asthma and allergic rhinitis patients on allergen immunotherapy 免疫介质在哮喘和变应性鼻炎患者变应原免疫治疗随访中的作用
Pub Date : 2020-07-01 DOI: 10.4103/ijaai.ijaai_12_20
Raj Kumar, P. Mrigpuri, Indu Bisht, Kamal Singh, M. Kumar, S. Spalgais
BACKGROUND: Bronchial asthma (BA) is characterized by chronic airway inflammation. Many studies have shown a significant overlap between BA and allergic rhinitis (AR). Specific allergen immunotherapy (AIT) is effective for the treatment of BA and AR. Only limited studies have evaluated the role of immunological parameters to assess the response in patients on AIT. Hence, this study was done to assess the role of interleukin-4 (IL-4), IL-5, and IL-6 in the follow-up of patients of BA and AR on AIT. MATERIALS AND METHODS: This study was conducted on diagnosed cases of BA, AR, and BA with AR attending the outpatient department who were started on subcutaneous immunotherapy as per the standard Indian guidelines. Blood samples were collected at the beginning of the treatment and every 3 months thereafter for a period of 51 months, and serum IL-4, IL-5, and IL-6 levels were measured. RESULTS: In this study, 170 patients were enrolled over a period of 51 months. Out of 170, 80 (47.1%) patients had completed 1 year of treatment with AIT at the end of 51 months of follow-up. Significant reduction was observed in IL-4, IL-5, and IL-6 levels during the treatment with AIT over a period of 12 months. CONCLUSION: Our study suggests a possible role of IL-4, IL-5, and IL-6 in the follow-up of BA and AR patients; however, further studies are needed in this area.
背景:支气管哮喘(BA)以慢性气道炎症为特征。许多研究表明BA与变应性鼻炎(AR)有明显的重叠。特异性过敏原免疫疗法(AIT)对BA和AR的治疗是有效的。只有有限的研究评估了免疫参数在评估AIT患者反应中的作用。因此,本研究旨在评估白细胞介素-4 (IL-4)、IL-5、IL-6在BA和AR患者AIT随访中的作用。材料和方法:本研究是在门诊确诊的BA、AR和BA合并AR的病例中进行的,这些病例根据印度标准指南开始进行皮下免疫治疗。治疗开始及治疗后每3个月采集一次血样,测定血清IL-4、IL-5、IL-6水平,共51个月。结果:在这项为期51个月的研究中,170名患者入组。在170例患者中,在51个月的随访结束时,80例(47.1%)患者完成了1年的AIT治疗。在12个月的AIT治疗期间,IL-4、IL-5和IL-6水平显著降低。结论:我们的研究提示IL-4、IL-5和IL-6在BA和AR患者的随访中可能发挥作用;然而,这一领域还需要进一步的研究。
{"title":"Role of immunological mediators in the follow-up of asthma and allergic rhinitis patients on allergen immunotherapy","authors":"Raj Kumar, P. Mrigpuri, Indu Bisht, Kamal Singh, M. Kumar, S. Spalgais","doi":"10.4103/ijaai.ijaai_12_20","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_12_20","url":null,"abstract":"BACKGROUND: Bronchial asthma (BA) is characterized by chronic airway inflammation. Many studies have shown a significant overlap between BA and allergic rhinitis (AR). Specific allergen immunotherapy (AIT) is effective for the treatment of BA and AR. Only limited studies have evaluated the role of immunological parameters to assess the response in patients on AIT. Hence, this study was done to assess the role of interleukin-4 (IL-4), IL-5, and IL-6 in the follow-up of patients of BA and AR on AIT. MATERIALS AND METHODS: This study was conducted on diagnosed cases of BA, AR, and BA with AR attending the outpatient department who were started on subcutaneous immunotherapy as per the standard Indian guidelines. Blood samples were collected at the beginning of the treatment and every 3 months thereafter for a period of 51 months, and serum IL-4, IL-5, and IL-6 levels were measured. RESULTS: In this study, 170 patients were enrolled over a period of 51 months. Out of 170, 80 (47.1%) patients had completed 1 year of treatment with AIT at the end of 51 months of follow-up. Significant reduction was observed in IL-4, IL-5, and IL-6 levels during the treatment with AIT over a period of 12 months. CONCLUSION: Our study suggests a possible role of IL-4, IL-5, and IL-6 in the follow-up of BA and AR patients; however, further studies are needed in this area.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"71 7 1","pages":"87 - 91"},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83613514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spectrum of diagnosis of hereditary angioedema: Seven case reports 遗传性血管性水肿的诊断谱:附7例报告
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_33_19
P. Kathuria, M. Rai, Neelam Kathuria
Hereditary angioedema (HAE) is a potentially life-threatening disorder, due to a mutation in complement one-inhibitor (C1-INH) gene, which blocks the activity of various components of complement – fibrinolytic and bradykinin control system. Our seven cases of HAE give different clinical presentations of TYPE I/II/III HAE as facial, abdominal, laryngeal, and genital involvement along with comorbidities (5 cases) such as hypothyroidism, rhinosinusitis, and hypothalamic–pituitary–adrenal suppression, and four cases have had history of recurrent abdominal attacks. Treatment with Pdc-INH concentrate and self-administrated Icatibant provides consistent and reliable efficacy in those who have had multiple successive HAE attacks, with the involvement of all body parts. However, if pdc-INH concentrate is not available, then fresh frozen plasma and androgens (Danazol) can be used in emergency. Our cases demonstrate the importance of diligent clinical and family history with special tests: C4, C1-INH quantitative, and C1-INH functional.
遗传性血管性水肿(HAE)是一种潜在威胁生命的疾病,由于补体1-抑制剂(C1-INH)基因突变,可阻断补体-纤维蛋白溶解和缓激素控制系统的各种成分的活性。我们的7例HAE患者表现为I/II/III型HAE的不同临床表现,包括面部、腹部、喉部和生殖器受累,并伴有合并症(5例),如甲状腺功能减退、鼻窦炎和下丘脑-垂体-肾上腺抑制,4例有复发性腹部发作史。Pdc-INH浓缩物和自我给药的伊卡班特治疗对那些多次连续HAE发作且累及所有身体部位的患者提供一致和可靠的疗效。但是,如果没有pcc - inh浓缩物,则可在紧急情况下使用新鲜冷冻血浆和雄激素(达那唑)。我们的病例证明了临床和家族史与特殊测试的重要性:C4, C1-INH定量和C1-INH功能。
{"title":"Spectrum of diagnosis of hereditary angioedema: Seven case reports","authors":"P. Kathuria, M. Rai, Neelam Kathuria","doi":"10.4103/ijaai.ijaai_33_19","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_33_19","url":null,"abstract":"Hereditary angioedema (HAE) is a potentially life-threatening disorder, due to a mutation in complement one-inhibitor (C1-INH) gene, which blocks the activity of various components of complement – fibrinolytic and bradykinin control system. Our seven cases of HAE give different clinical presentations of TYPE I/II/III HAE as facial, abdominal, laryngeal, and genital involvement along with comorbidities (5 cases) such as hypothyroidism, rhinosinusitis, and hypothalamic–pituitary–adrenal suppression, and four cases have had history of recurrent abdominal attacks. Treatment with Pdc-INH concentrate and self-administrated Icatibant provides consistent and reliable efficacy in those who have had multiple successive HAE attacks, with the involvement of all body parts. However, if pdc-INH concentrate is not available, then fresh frozen plasma and androgens (Danazol) can be used in emergency. Our cases demonstrate the importance of diligent clinical and family history with special tests: C4, C1-INH quantitative, and C1-INH functional.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"259 1","pages":"49 - 52"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74367207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensitization to indoor allergens in children with bronchial asthma 支气管哮喘儿童对室内过敏原的致敏
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_14_19
K. Chauhan, Shetanshu Srivastava, R. Prasad
BACKGROUND: Children with asthma have a high prevalence of environmental allergies. Sensitization to various allergens, especially to indoor allergens is crucial for effective measures for asthma management. Indian data on allergic sensitization in children is scarce, necessitating the need of the study. METHODS: A Cross-sectional study was conducted to determine the indoor allergen sensitization in 100 asthmatic children aged 5 to 15 yrs. They underwent skin prick test for indoor allergen house dust mite cockroach, cat, dog dander, house fly, candida, aspergillus, and mosquito. RESULTS: In the study sensitization to house dust mite was 93%. 39% were sensitized to Candida 36% to cockroach,23% housefly and 22%to dog dander and Aspergillus and 13% to mosquito and cat dander. Allergen sensitivity rate for atleast one allergen was 94% which was significant. Mean No. of allergens for which sensitization was seen is 2.57±1.77. Comorbidities were present in 35% of cases.7% had urticarial and allergic conjunctivitis each. CONCLUSION: Asthmatic children showed high sensitization to indoor allergen and the most common allergen found was house dust mite
背景:哮喘患儿环境过敏发生率高。对各种过敏原的致敏,特别是对室内过敏原的致敏对于哮喘管理的有效措施至关重要。印度关于儿童过敏致敏的数据很少,因此有必要进行这项研究。方法:采用横断面研究方法测定100例5 ~ 15岁哮喘儿童室内过敏原致敏情况。对室内过敏原进行皮肤点刺试验,检测室内尘螨、蟑螂、猫、狗皮屑、家蝇、假丝酵母菌、曲霉和蚊子。结果:本研究对室内尘螨的致敏率为93%。对念珠菌敏感的占39%,对蟑螂敏感的占36%,对家蝇敏感的占23%,对狗皮屑和曲霉菌敏感的占22%,对蚊子皮屑和猫皮屑敏感的占13%。对至少一种过敏原的敏感率为94%,这是显著的。意思是没有。致敏率为2.57±1.77。35%的病例存在合并症。7%的患者有荨麻疹和过敏性结膜炎。结论:哮喘患儿对室内过敏原有较高的致敏性,最常见的过敏原是屋尘螨
{"title":"Sensitization to indoor allergens in children with bronchial asthma","authors":"K. Chauhan, Shetanshu Srivastava, R. Prasad","doi":"10.4103/ijaai.ijaai_14_19","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_14_19","url":null,"abstract":"BACKGROUND: Children with asthma have a high prevalence of environmental allergies. Sensitization to various allergens, especially to indoor allergens is crucial for effective measures for asthma management. Indian data on allergic sensitization in children is scarce, necessitating the need of the study. METHODS: A Cross-sectional study was conducted to determine the indoor allergen sensitization in 100 asthmatic children aged 5 to 15 yrs. They underwent skin prick test for indoor allergen house dust mite cockroach, cat, dog dander, house fly, candida, aspergillus, and mosquito. RESULTS: In the study sensitization to house dust mite was 93%. 39% were sensitized to Candida 36% to cockroach,23% housefly and 22%to dog dander and Aspergillus and 13% to mosquito and cat dander. Allergen sensitivity rate for atleast one allergen was 94% which was significant. Mean No. of allergens for which sensitization was seen is 2.57±1.77. Comorbidities were present in 35% of cases.7% had urticarial and allergic conjunctivitis each. CONCLUSION: Asthmatic children showed high sensitization to indoor allergen and the most common allergen found was house dust mite","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"37 1","pages":"39 - 42"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84086203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Covid-19 immune mechanisms: A systematic review Covid-19免疫机制:系统综述
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_22_20
Shalini Gandhi, Sandeep Sharma, Purva Shoor, J. Sorout, Abhay Raina, R. Raina, Urvashi Miglani, U. Chaudhari, Shivi Srivastava
There is a new public health crises threatening globally with the emergence and spread of 2019 novel coronavirus or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is the seventh member of the coronavirus (CoV) family, which infects humans and to which the Middle East Respiratory Syndrome CoV (MERS)-and SARS-CoV also belong. SARS-CoV-2 is a newly emerging human infectious CoV that causes COVID-19, which has been recognized as a pandemic by the World Health Organization on March 11. The most recent outbreak initially presented as pneumonia of unknown etiology as COVID-19 is a pneumonia-like disease with a group of symptoms including fever, dry cough and shortness of breath in a cluster of patients in December 2019 Wuhan, China. The body's immune system tries to protect the body from this pathogen. And as due to its surge in the body, various respiratory and other system-related complications increased. Therefore, in this article, COVID-19 immunopathogenesis is briefly reviewed. Through this review, we try to explain the molecular immune pathogenesis and diagnosis of COVID-19 (SARS-CoV-2) infection, based on the recent research progress of SARS-CoV-2 and the knowledge from researches on SARS-CoV and MERS-CoV.
随着2019年新型冠状病毒或严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)的出现和传播,全球面临新的公共卫生危机。它是冠状病毒(CoV)家族的第七名成员,该家族感染人类,中东呼吸综合征(MERS)和SARS-CoV也属于该家族。新冠病毒(SARS-CoV-2)是导致新冠病毒(COVID-19)的新型人类传染性冠状病毒(CoV), 11日被世界卫生组织(who)认定为大流行。最近的疫情最初表现为病因不明的肺炎COVID-19,是2019年12月在中国武汉发生的一群患者中出现的一组症状,包括发烧、干咳和呼吸短促。人体的免疫系统试图保护身体免受这种病原体的侵害。由于它在体内的激增,各种呼吸系统和其他系统相关的并发症也增加了。因此,本文就COVID-19的免疫发病机制作一综述。本文结合近年来SARS-CoV-2的研究进展以及SARS-CoV和MERS-CoV的研究成果,对COVID-19 (SARS-CoV-2)感染的分子免疫发病机制和诊断进行综述。
{"title":"Covid-19 immune mechanisms: A systematic review","authors":"Shalini Gandhi, Sandeep Sharma, Purva Shoor, J. Sorout, Abhay Raina, R. Raina, Urvashi Miglani, U. Chaudhari, Shivi Srivastava","doi":"10.4103/ijaai.ijaai_22_20","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_22_20","url":null,"abstract":"There is a new public health crises threatening globally with the emergence and spread of 2019 novel coronavirus or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is the seventh member of the coronavirus (CoV) family, which infects humans and to which the Middle East Respiratory Syndrome CoV (MERS)-and SARS-CoV also belong. SARS-CoV-2 is a newly emerging human infectious CoV that causes COVID-19, which has been recognized as a pandemic by the World Health Organization on March 11. The most recent outbreak initially presented as pneumonia of unknown etiology as COVID-19 is a pneumonia-like disease with a group of symptoms including fever, dry cough and shortness of breath in a cluster of patients in December 2019 Wuhan, China. The body's immune system tries to protect the body from this pathogen. And as due to its surge in the body, various respiratory and other system-related complications increased. Therefore, in this article, COVID-19 immunopathogenesis is briefly reviewed. Through this review, we try to explain the molecular immune pathogenesis and diagnosis of COVID-19 (SARS-CoV-2) infection, based on the recent research progress of SARS-CoV-2 and the knowledge from researches on SARS-CoV and MERS-CoV.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"11 1","pages":"23 - 27"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75787720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Nebulization in the pandemic of coronavirus disease 2019 2019冠状病毒病大流行中的雾化
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_29_20
S. Katiyar, Sandeep Katiyar
Inhaled therapy is the cornerstone in the management of obstructive airway diseases (OADs). Nebulization is often used for the delivery of bronchodilators and corticosteroids among the elderly and children. The present pandemic of coronavirus disease 2019 (COVID-19), caused by a newly identified, highly contagious, novel coronavirus, called severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is responsible for great morbidity and mortality globally. There is a great concern regarding person-to-person transmissibility of this virus. There is also a great concern of viral transmission of this virus to the health-care personnel and the bystanders through aerosol-generating procedures including frequently used nebulization therapy. Most of the patients with OAD, during the current pandemic, who were undergoing nebulization therapy, on getting infected with SARS-CoV-2 or on its suspicion, have been shifted to other handheld devices out of fear of transmission of infection. Presently, there exist not enough evidences either on the safety or on the risk of transmissibility of SARS-CoV-2 during nebulization in COVID-19 patients. In addition, there are concerns about nebulization in OAD cases even in the absence of COVID-19 and about the use of inhaled or systemic corticosteroids in these cases. We have made some observations based on all the current information available related to these issues, which may help provide some guidance in the use of nebulizer therapy and also discussed the measures to be taken to minimize the risk of infection, if any, during the procedure.
吸入治疗是管理阻塞性气道疾病(OADs)的基石。在老年人和儿童中,雾化常用于支气管扩张剂和皮质类固醇的输送。目前的2019冠状病毒病(COVID-19)大流行是由一种新发现的高度传染性新型冠状病毒(称为严重急性呼吸综合征-冠状病毒-2 (SARS-CoV-2))引起的,在全球造成了很高的发病率和死亡率。人们非常关注这种病毒的人际传播。人们还非常担心,这种病毒会通过产生气溶胶的程序,包括经常使用的雾化疗法,传播给卫生保健人员和旁观者。在此次大流行期间,大部分OAD患者在被感染或疑似感染时正在接受雾化治疗,但由于担心感染的传播,他们都转移到了其他手持设备上。目前,COVID-19患者雾化过程中SARS-CoV-2的安全性和传播风险尚无足够的证据。此外,即使在没有COVID-19的情况下,对OAD病例进行雾化治疗以及在这些病例中使用吸入或全身皮质类固醇也令人担忧。我们根据所有与这些问题相关的现有信息进行了一些观察,这可能有助于为雾化器治疗的使用提供一些指导,并讨论了在治疗过程中应采取的措施,以尽量减少感染的风险。
{"title":"Nebulization in the pandemic of coronavirus disease 2019","authors":"S. Katiyar, Sandeep Katiyar","doi":"10.4103/ijaai.ijaai_29_20","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_29_20","url":null,"abstract":"Inhaled therapy is the cornerstone in the management of obstructive airway diseases (OADs). Nebulization is often used for the delivery of bronchodilators and corticosteroids among the elderly and children. The present pandemic of coronavirus disease 2019 (COVID-19), caused by a newly identified, highly contagious, novel coronavirus, called severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is responsible for great morbidity and mortality globally. There is a great concern regarding person-to-person transmissibility of this virus. There is also a great concern of viral transmission of this virus to the health-care personnel and the bystanders through aerosol-generating procedures including frequently used nebulization therapy. Most of the patients with OAD, during the current pandemic, who were undergoing nebulization therapy, on getting infected with SARS-CoV-2 or on its suspicion, have been shifted to other handheld devices out of fear of transmission of infection. Presently, there exist not enough evidences either on the safety or on the risk of transmissibility of SARS-CoV-2 during nebulization in COVID-19 patients. In addition, there are concerns about nebulization in OAD cases even in the absence of COVID-19 and about the use of inhaled or systemic corticosteroids in these cases. We have made some observations based on all the current information available related to these issues, which may help provide some guidance in the use of nebulizer therapy and also discussed the measures to be taken to minimize the risk of infection, if any, during the procedure.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"139 1","pages":"8 - 14"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86547870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Selective immunoglobulin M deficiency: An underestimated immunodeficiency disorder – not so rare 选择性免疫球蛋白M缺乏症:一种被低估的免疫缺陷疾病——并不罕见
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_34_19
A. Agarwal
Immunoglobulin M (IgM) is the first antibody to be produced during an immune response, and most of the primary humoral immune response is mediated by IgM. Selective IgM deficiency (sIgMD) is a rare immune disorder that has been reported in the association with serious infections. Patients with sIgMD may be asymptomatic; however, approximately 80% of patients present with infections with bacteria, viruses, or protozoa or with an associated allergic, malignant, or autoimmune condition. sIgMD is usually identified when evaluating a patient for recurrent or serious infections. Attempts should be made to document the infection, as well as the responsible organism, whenever possible. It is a diagnosis of exclusion, and formal diagnostic criteria have not been established. We report three adult cases that were diagnosed to have sIgMD during the evaluation for serious polymicrobial infections with bacteria, fungi, mycobacterium, and viruses. One of them was diagnosed to have associated lymphocytic leukemia. All were successfully managed with intravenous Immunoglobulin (Ig), antibiotics, antiviral, supportive treatment, and discharged. We conclude that patients presenting with polymicrobial infections with encapsulated bacteria, fungi, mycobacterium, and viruses should be evaluated for specific antibody deficiency responses, and they appear to improve clinically on Ig therapy. It appears that the disorder is underdiagnosed.
免疫球蛋白M (IgM)是免疫应答过程中首先产生的抗体,大多数原发性体液免疫应答是由IgM介导的。选择性IgM缺乏症(sIgMD)是一种罕见的免疫疾病,已报道与严重感染有关。sIgMD患者可能无症状;然而,大约80%的患者存在细菌、病毒或原生动物感染或相关的过敏、恶性或自身免疫性疾病。sIgMD通常在评估患者的复发性或严重感染时确定。在可能的情况下,应尝试记录感染情况以及负责任的生物体。这是一种排除性诊断,正式的诊断标准尚未建立。我们报告了三例成人病例,在评估严重的细菌、真菌、分枝杆菌和病毒多微生物感染时被诊断为sIgMD。其中一人被诊断患有相关淋巴细胞白血病。所有患者均经静脉注射免疫球蛋白(Ig)、抗生素、抗病毒药物及支持治疗成功出院。我们的结论是,出现包封细菌、真菌、分枝杆菌和病毒的多微生物感染的患者应该进行特异性抗体缺乏反应的评估,并且他们在Ig治疗后在临床上似乎有所改善。这种疾病似乎没有得到充分的诊断。
{"title":"Selective immunoglobulin M deficiency: An underestimated immunodeficiency disorder – not so rare","authors":"A. Agarwal","doi":"10.4103/ijaai.ijaai_34_19","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_34_19","url":null,"abstract":"Immunoglobulin M (IgM) is the first antibody to be produced during an immune response, and most of the primary humoral immune response is mediated by IgM. Selective IgM deficiency (sIgMD) is a rare immune disorder that has been reported in the association with serious infections. Patients with sIgMD may be asymptomatic; however, approximately 80% of patients present with infections with bacteria, viruses, or protozoa or with an associated allergic, malignant, or autoimmune condition. sIgMD is usually identified when evaluating a patient for recurrent or serious infections. Attempts should be made to document the infection, as well as the responsible organism, whenever possible. It is a diagnosis of exclusion, and formal diagnostic criteria have not been established. We report three adult cases that were diagnosed to have sIgMD during the evaluation for serious polymicrobial infections with bacteria, fungi, mycobacterium, and viruses. One of them was diagnosed to have associated lymphocytic leukemia. All were successfully managed with intravenous Immunoglobulin (Ig), antibiotics, antiviral, supportive treatment, and discharged. We conclude that patients presenting with polymicrobial infections with encapsulated bacteria, fungi, mycobacterium, and viruses should be evaluated for specific antibody deficiency responses, and they appear to improve clinically on Ig therapy. It appears that the disorder is underdiagnosed.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"284 1","pages":"43 - 48"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76851407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
COVID-19: A global crisis COVID-19:一场全球危机
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_16_20
N. Sarangdhar, S. Gaur
{"title":"COVID-19: A global crisis","authors":"N. Sarangdhar, S. Gaur","doi":"10.4103/ijaai.ijaai_16_20","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_16_20","url":null,"abstract":"","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"32 1","pages":"1 - 4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73863118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The epidemiological and trending pattern of nCOVID-19 in the state of Rajasthan, India 印度拉贾斯坦邦covid -19的流行病学和趋势模式
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_17_20
S. Bhandari, Ajeet Singh, S. Banerjee, Raman Sharma, G. Rankawat, Vishal Gupta, P. Keswani, Ashwini Mathur, A. Agarwal, S. Sharma, P. Meena
PURPOSE: The present study was undertaken to investigate the behavioral distribution pattern and progression of coronavirus disease 2019 (COVID-19) across age and gender in the state of Rajasthan, India, inherently distinctive and native to localized part of the globe giving requisite information and paraphernalia to designate advisory board of the state to design and frame customized policy for demands of the state as per the trending pattern relative to age and sex distribution, profile of new infected cases, recovery rate, and case fatality rate. METHODS: The present ongoing study assessed patients admitted till April 22, 2020, across the state of Rajasthan, India, with reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 test. Analyses of the patients included characteristic age and gender distribution through the geographic identities of state along with the time trending pattern of newly infected patients, recovered patients, and case fatality rate. RESULTS: A total of 1888 sample patient population of RT-PCR-confirmed COVID-19 was evaluated, with the majority of sample patient population being in young adult age group with a mean age of 34.42 years. Nearly 11.65% of the patients were below 15 years of age, 34.79% were in the age range of 16–30 years, 25.90% were in the age group of 31–45 years, and 17.69% were in the age group of 46–60 years, with only 9.95% of the patient population being in the age group of above 60 years. Interestingly, 11.65% of patients with COVID-19 were in the pediatric age group. The percent of affected females (37.35%) was much less than that compared to males (62.65%), with an average sex ratio of 0.59. Across the sample patient population of 1888, 543 patients recovered fully, 25 patients died, and 1320 cases were active in the said time frame, with an average recovery rate of 28.76% and a case fatality rate of 1.32%, and the remaining 69.91% of the patient population made up the active case group. The timeline and the trending pattern of COVID-19 in the state of Rajasthan was suggestive of an increasing rise of number of new cases with antecedent mortality, though a reassuring concomitant rise in the recovery rate of patients could also be appreciated. The infective COVID-19 dictum of spread through contact could very well be appreciated in select geographic hotspots and/or zones, and 108 sample patient population was from out of Rajasthan. CONCLUSION: It was interesting to observe that majority of the resident population of the state of Rajasthan that was COVID-19 positive was in the young adult age group of 30–50 years inclusive of pediatric patients, an observation that is different from reports as documented from across the world. Male population seemed to be more prone to infection. The time frame in which the evaluation was done is suggestive of an increasing trend in the number of new cases with antecedent case fatality, though recovery was also on the rise indicative of a potentia
目的:本研究旨在调查印度拉贾斯坦邦2019年冠状病毒病(COVID-19)在年龄和性别上的行为分布模式和进展,该疾病具有固有的独特性和全球本地化的特点,为指定邦顾问委员会提供必要的信息和工具,以便根据年龄和性别分布的趋势模式设计和制定定制的政策。新感染病例、康复率和病死率的概况。方法:本研究对印度拉贾斯坦邦截至2020年4月22日入院的患者进行了评估,采用逆转录聚合酶链反应(RT-PCR)确诊的COVID-19检测。通过州的地理特征分析患者的特征年龄和性别分布,以及新感染患者、康复患者和病死率的时间趋势。结果:共评估了1888例rt - pcr确诊的COVID-19样本患者群体,样本患者群体以青年组居多,平均年龄34.42岁。15岁以下患者占11.65%,16-30岁占34.79%,31-45岁占25.90%,46-60岁占17.69%,60岁以上患者仅占9.95%。有趣的是,11.65%的COVID-19患者属于儿科年龄组。女性感染比例(37.35%)远低于男性(62.65%),平均性别比为0.59。在1888例患者中,543例患者完全康复,25例患者死亡,1320例患者活跃,平均康复率为28.76%,病死率为1.32%,其余69.91%的患者为活跃病例组。拉贾斯坦邦COVID-19的时间线和趋势模式表明,先前死亡的新病例数量不断增加,尽管患者的康复率也随之上升,这令人欣慰。在选定的地理热点和/或地区,可以很好地理解COVID-19通过接触传播的传染性格言,108例样本患者来自拉贾斯坦邦以外。结论:有趣的是,拉贾斯坦邦的大多数COVID-19阳性常住人口都是30-50岁的年轻人,包括儿科患者,这一观察结果与世界各地记录的报告不同。男性人群似乎更容易感染。进行评估的时间框架表明,以前有病死率的新病例数量呈增加趋势,尽管恢复情况也在上升,表明负荷可能在减少。通过接触者追踪建立新冠肺炎患者地理分布图。
{"title":"The epidemiological and trending pattern of nCOVID-19 in the state of Rajasthan, India","authors":"S. Bhandari, Ajeet Singh, S. Banerjee, Raman Sharma, G. Rankawat, Vishal Gupta, P. Keswani, Ashwini Mathur, A. Agarwal, S. Sharma, P. Meena","doi":"10.4103/ijaai.ijaai_17_20","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_17_20","url":null,"abstract":"PURPOSE: The present study was undertaken to investigate the behavioral distribution pattern and progression of coronavirus disease 2019 (COVID-19) across age and gender in the state of Rajasthan, India, inherently distinctive and native to localized part of the globe giving requisite information and paraphernalia to designate advisory board of the state to design and frame customized policy for demands of the state as per the trending pattern relative to age and sex distribution, profile of new infected cases, recovery rate, and case fatality rate. METHODS: The present ongoing study assessed patients admitted till April 22, 2020, across the state of Rajasthan, India, with reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19 test. Analyses of the patients included characteristic age and gender distribution through the geographic identities of state along with the time trending pattern of newly infected patients, recovered patients, and case fatality rate. RESULTS: A total of 1888 sample patient population of RT-PCR-confirmed COVID-19 was evaluated, with the majority of sample patient population being in young adult age group with a mean age of 34.42 years. Nearly 11.65% of the patients were below 15 years of age, 34.79% were in the age range of 16–30 years, 25.90% were in the age group of 31–45 years, and 17.69% were in the age group of 46–60 years, with only 9.95% of the patient population being in the age group of above 60 years. Interestingly, 11.65% of patients with COVID-19 were in the pediatric age group. The percent of affected females (37.35%) was much less than that compared to males (62.65%), with an average sex ratio of 0.59. Across the sample patient population of 1888, 543 patients recovered fully, 25 patients died, and 1320 cases were active in the said time frame, with an average recovery rate of 28.76% and a case fatality rate of 1.32%, and the remaining 69.91% of the patient population made up the active case group. The timeline and the trending pattern of COVID-19 in the state of Rajasthan was suggestive of an increasing rise of number of new cases with antecedent mortality, though a reassuring concomitant rise in the recovery rate of patients could also be appreciated. The infective COVID-19 dictum of spread through contact could very well be appreciated in select geographic hotspots and/or zones, and 108 sample patient population was from out of Rajasthan. CONCLUSION: It was interesting to observe that majority of the resident population of the state of Rajasthan that was COVID-19 positive was in the young adult age group of 30–50 years inclusive of pediatric patients, an observation that is different from reports as documented from across the world. Male population seemed to be more prone to infection. The time frame in which the evaluation was done is suggestive of an increasing trend in the number of new cases with antecedent case fatality, though recovery was also on the rise indicative of a potentia","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"76 1","pages":"28 - 33"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75199762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of asthma and allergic diseases during the coronavirus disease 2019 pandemic in India 2019年印度冠状病毒大流行期间哮喘和过敏性疾病的管理
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_20_20
Nagaraju Kuravi, K. Nagaraju, Venkata Voorakaranam
Coronavirus disease 2019 (COVID 19) is caused by the novel coronavirus, which has affected 184 countries and the WHO has declared it a pandemic on March 2020. Allergic diseases such as allergic rhinitis and asthma are exaggerated by viral infections. Symptoms of allergic diseases overlap with COVID 19. Current recommendations include following social distancing and frequent hand washing. Confusion exists regarding the use of corticosteroids, biologicals, and immunotherapy for the treatment of allergic diseases during COVID 19 season. Due to the use of Personal Protective Equipments, reports of contact dermatitis are emerging among health-care workers. Remote consultation, like telemedicine, is a valuable tool in this pandemic. This article aims to provide guidance on the management of allergic diseases taking into consideration existing evidence and guidelines from international organizations and the feasibility of implementation in India.
2019冠状病毒病(COVID - 19)是由新型冠状病毒引起的,已经影响了184个国家,世界卫生组织于2020年3月宣布其为大流行。变应性鼻炎和哮喘等过敏性疾病会因病毒感染而加重。过敏性疾病的症状与COVID - 19有重叠。目前的建议包括保持社交距离和经常洗手。在COVID - 19季节,使用皮质类固醇、生物制剂和免疫疗法治疗过敏性疾病存在混淆。由于使用个人防护设备,卫生保健工作者中出现了接触性皮炎的报告。与远程医疗一样,远程咨询是应对此次大流行的宝贵工具。本文旨在考虑到现有的证据和国际组织的指南以及在印度实施的可行性,为变态反应性疾病的管理提供指导。
{"title":"Management of asthma and allergic diseases during the coronavirus disease 2019 pandemic in India","authors":"Nagaraju Kuravi, K. Nagaraju, Venkata Voorakaranam","doi":"10.4103/ijaai.ijaai_20_20","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_20_20","url":null,"abstract":"Coronavirus disease 2019 (COVID 19) is caused by the novel coronavirus, which has affected 184 countries and the WHO has declared it a pandemic on March 2020. Allergic diseases such as allergic rhinitis and asthma are exaggerated by viral infections. Symptoms of allergic diseases overlap with COVID 19. Current recommendations include following social distancing and frequent hand washing. Confusion exists regarding the use of corticosteroids, biologicals, and immunotherapy for the treatment of allergic diseases during COVID 19 season. Due to the use of Personal Protective Equipments, reports of contact dermatitis are emerging among health-care workers. Remote consultation, like telemedicine, is a valuable tool in this pandemic. This article aims to provide guidance on the management of allergic diseases taking into consideration existing evidence and guidelines from international organizations and the feasibility of implementation in India.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"125 1","pages":"15 - 22"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89883041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical, radiological, and immunological assessment of allergic bronchopulmonary aspergillosis 过敏性支气管肺曲霉病的临床、放射学和免疫学评估
Pub Date : 2020-01-01 DOI: 10.4103/ijaai.ijaai_28_19
Anshika Jindal, Y. Rathore, Shubhra Jain, V. Jain, V. Joshi
INTRODUCTION: Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated lung disease, predominantly in patients with asthma and is caused by hypersensitivity to colonized dimorphic fungus Aspergillus, commonly Aspergillus fumigatus. Early diagnosis with recognition and treatment of chest radiographic infiltrates appears to prevent progression to end stage fibrosis. Many cases are mistreated as pulmonary tuberculosis or recurrent pneumonia and are deferred for specific treatment of ABPA. AIM AND OBJECTIVES: This study aims to know the clinical, radiological, and immunological profile of patients diagnosed with ABPA reporting to the Institute of Respiratory Disease, SMS College, Jaipur and Mahatma Gandhi Medical College, Jaipur. MATERIALS AND METHODS: Hospital-based prospective, observational, cross-sectional study was conducted in 48 Patients having history of bronchial asthma, pulmonary infiltrate/shadows on chest X-ray were subjected to routine investigations, immunological tests including modified skin prick test with specific IgE against A. fumigatus and specific precipitins against A. fumigatus. RESULT: In this study, maximum predominance with age group of 21–40 years irrespective of sexpattern. Maximum patients were having bronchial asthma of 2–10 years duration. Cough, breathlessness, and wheezing were main clinical features. In 80% cases, total eosinophilic counts were more than 1000.58.4% sputum were fungal culture positive, maximum for A. fumigatus. All cases showed modified kinprick test positivity against A. fumigatus. Maximum patients high-resolution computed tomography chest had central bronchiectasis. 37% cases had raised total serum IgE (range 1000–5000). Specific IgE against A. fumigatus were positive in 24 patients. 87.5% patients were positive for specific precipitins. CONCLUSION: In this study, ABPA was found more commonly in people with chronic asthma of productive age group, i.e., 20–40 years and farmers by occupation. Most of the people were diagnosed as having pulmonary tuberculosis and deferred specific treatment for a long time. More knowledge about ABPA to physicians could possibly cut short the time between suffering, diagnosis, and proper treatment of these patients.
简介:过敏性支气管肺曲霉病(ABPA)是一种免疫介导的肺部疾病,主要发生在哮喘患者中,由对定殖的二态真菌曲霉(通常是烟曲霉)的超敏反应引起。早期诊断,识别和治疗胸片浸润似乎可以防止进展到终末期纤维化。许多病例被误诊为肺结核或复发性肺炎,推迟了ABPA的特异性治疗。目的和目的:本研究旨在了解向斋浦尔SMS学院呼吸疾病研究所和斋浦尔圣雄甘地医学院报告的被诊断为ABPA的患者的临床、放射学和免疫学概况。材料与方法:对48例有支气管哮喘病史的患者进行了以医院为基础的前瞻性、观察性、横断面研究,进行了常规检查,包括改良皮肤点刺试验,对烟曲霉特异性IgE和烟曲霉特异性沉淀进行了免疫检查。结果:在本研究中,21-40岁年龄组与性别模式无关。支气管哮喘患者最多,病程2 ~ 10年。咳嗽、呼吸困难和喘息是主要的临床特征。80%的痰中嗜酸性粒细胞总数大于1000个,58.4%的痰中真菌培养阳性,烟曲霉阳性最多。所有病例的改良刺点试验均呈烟螨阳性。大多数患者的高分辨率计算机断层扫描胸部显示中枢性支气管扩张。37%的患者血清总IgE升高(范围1000-5000)。24例患者烟曲霉特异性IgE阳性。87.5%的患者特异性沉淀阳性。结论:在本研究中,慢性哮喘患者ABPA以20-40岁生产年龄组和职业农民为常见病。大多数人被诊断为肺结核,并推迟了很长时间的具体治疗。向医生提供更多关于ABPA的知识,可能会缩短这些患者的痛苦、诊断和适当治疗之间的时间。
{"title":"Clinical, radiological, and immunological assessment of allergic bronchopulmonary aspergillosis","authors":"Anshika Jindal, Y. Rathore, Shubhra Jain, V. Jain, V. Joshi","doi":"10.4103/ijaai.ijaai_28_19","DOIUrl":"https://doi.org/10.4103/ijaai.ijaai_28_19","url":null,"abstract":"INTRODUCTION: Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated lung disease, predominantly in patients with asthma and is caused by hypersensitivity to colonized dimorphic fungus Aspergillus, commonly Aspergillus fumigatus. Early diagnosis with recognition and treatment of chest radiographic infiltrates appears to prevent progression to end stage fibrosis. Many cases are mistreated as pulmonary tuberculosis or recurrent pneumonia and are deferred for specific treatment of ABPA. AIM AND OBJECTIVES: This study aims to know the clinical, radiological, and immunological profile of patients diagnosed with ABPA reporting to the Institute of Respiratory Disease, SMS College, Jaipur and Mahatma Gandhi Medical College, Jaipur. MATERIALS AND METHODS: Hospital-based prospective, observational, cross-sectional study was conducted in 48 Patients having history of bronchial asthma, pulmonary infiltrate/shadows on chest X-ray were subjected to routine investigations, immunological tests including modified skin prick test with specific IgE against A. fumigatus and specific precipitins against A. fumigatus. RESULT: In this study, maximum predominance with age group of 21–40 years irrespective of sexpattern. Maximum patients were having bronchial asthma of 2–10 years duration. Cough, breathlessness, and wheezing were main clinical features. In 80% cases, total eosinophilic counts were more than 1000.58.4% sputum were fungal culture positive, maximum for A. fumigatus. All cases showed modified kinprick test positivity against A. fumigatus. Maximum patients high-resolution computed tomography chest had central bronchiectasis. 37% cases had raised total serum IgE (range 1000–5000). Specific IgE against A. fumigatus were positive in 24 patients. 87.5% patients were positive for specific precipitins. CONCLUSION: In this study, ABPA was found more commonly in people with chronic asthma of productive age group, i.e., 20–40 years and farmers by occupation. Most of the people were diagnosed as having pulmonary tuberculosis and deferred specific treatment for a long time. More knowledge about ABPA to physicians could possibly cut short the time between suffering, diagnosis, and proper treatment of these patients.","PeriodicalId":53075,"journal":{"name":"Indian Journal of Allergy Asthma and Immunology","volume":"78 1","pages":"34 - 38"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91197775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Allergy Asthma and Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1